We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

SLSN:NASDAQSolesence, Inc. Analysis

Data as of 2026-05-01 - not real-time

$1.34

Latest Price

8/10Risk

Risk Level: High

Executive Summary

Solesence, Inc. is trading at $1.34, well below its 52‑week high of $5.63 but also beneath its long‑term SMA‑200 of $2.34, indicating a prolonged downtrend. Technical signals are mixed: the 20‑day SMA (1.23) sits above the 50‑day SMA (1.12) suggesting short‑term momentum, yet the MACD histogram remains modestly positive (0.019) and RSI is neutral at 58, reflecting limited upside pressure. Fundamentally, the company carries a high PE of 67, a PB of 5.36, and a debt‑to‑equity ratio exceeding 130, while operating and free cash flow are deeply negative, raising concerns about sustainability. Volatility is extreme at 132% over 30 days and beta exceeds 2, pointing to a stock that swings sharply with market moves. Recent material news includes the upcoming Q1 2026 earnings call on May 12, which may provide fresh guidance but does not yet offset the current financial strain. Overall, the combination of lofty valuation multiples, weak cash generation, and high market risk suggests caution for investors.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 7/10

Key Factors

  • Price below long‑term SMA‑200 indicating bearish trend
  • High valuation multiples (PE 67, PB 5.36) with weak cash flow
  • Elevated volatility and beta amplifying downside risk

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Potential catalyst from upcoming Q1 2026 earnings call
  • Short‑term SMA crossover offering limited upside
  • Continued uncertainty around cash generation and debt load

Long Term

> 3 years
Neutral
Model confidence: 4/10

Key Factors

  • Fundamental restructuring needed to improve margins
  • Consumer defensive sector provides some defensive qualities
  • Persistent high volatility and liquidity constraints

Key Metrics & Analysis

Financial Health

Revenue Growth-0.70%
Profit Margin2.88%
P/E Ratio67.0
ROE10.99%
ROA1.96%
Debt/Equity137.91
P/B Ratio5.4
Op. Cash Flow$-8567000
Free Cash Flow$-11546625

Technical Analysis

TrendNeutral
RSI57.6
Support$1.06
Resistance$1.49
MA 20$1.23
MA 50$1.12
MA 200$2.34
MACDBullish
VolumeDecreasing
Fear & Greed Index90.95

Valuation

GradeOvervalued
TypeValue

Risk Assessment

Beta2.13
Volatility132.07%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.